Post-earnings recap
Reported
Thu, Aug 13, 2026
EPS actual
$0.29
EPS est.
$0.26
EPS surprise
+11.54%
1-day move
+14.65%
CorMedix Inc. reported a positive surprise in earnings per share, which contributed to a significant stock increase of 14.65%. The lack of revenue data and management commentary leaves some uncertainty about the overall performance and future outlook. Investors may view the EPS beat as a positive sign, but the absence of additional context could lead to cautious sentiment moving forward.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.29 | N/A | +11.54% |
| Revenue | — | N/A | — |
No transcript is on record, and the analysis is based on numerical results only.
CorMedix Inc. is a pharmaceutical company focused on developing and commercializing innovative products to prevent and treat serious infections in patients with compromised immune systems. With a market cap of $1 billion, the company operates in the health care sector, which is increasingly important as the demand for effective treatments continues to grow.
Last quarter
In Q1-2026, CorMedix reported an EPS of $0.43, exceeding expectations by 24.64%. The stock rose 5.73% the following day, indicating positive market sentiment.
EPS beat streak
2Q
EPS beat rate
88%
Avg EPS surprise
+38.23%
Avg 1-day reaction
-3.67%
Investors are anticipating strong performance from CorMedix in the upcoming earnings report, especially after a positive surprise last quarter. However, the lack of analyst estimates adds uncertainty to expectations.
Bull case
If CorMedix beats EPS expectations again, it could reinforce investor confidence and lead to a significant stock price increase.
Bear case
Conversely, if the company fails to meet expectations or provides weak guidance, it could lead to a sharp decline in the stock price.
Key metrics to watch
Earnings Per Share (EPS)
$0.43EPS is a key indicator of the company's profitability and financial health, which investors will closely monitor this quarter.
Revenue Growth
N/ARevenue growth is crucial for understanding the company's market performance and demand for its products.
The print will turn on these.
Q1
Will CorMedix report an EPS of $0.43 or higher?
This specific EPS figure is critical as it will determine if the company continues its trend of beating expectations, which could significantly impact stock performance.
Q2
What guidance will management provide for future revenue growth?
Future revenue guidance will be essential for assessing the company's growth prospects and market position, influencing investor sentiment.
—
Est. EPS
—
Est. Rev
—
Impl. Move
±3.8%
Why consensus could be wrong
The Street may be underestimating CorMedix's ability to maintain its growth trajectory despite recent fluctuations in earnings.
Supporting evidence
CorMedix has consistently beaten EPS estimates in recent quarters, suggesting strong operational performance.
The options market is pricing a larger move than historical averages, indicating that traders expect significant volatility.
The company's innovative product pipeline could drive unexpected revenue growth, contrary to cautious market sentiment.
Key risk
If the EPS comes in below $0.34, it could validate the bearish outlook and lead to a reassessment of the company's growth potential.
Pre-commit to what would confirm each case.
The upcoming earnings report is pivotal as it will either reinforce the company's growth narrative or raise concerns about its profitability.
Bull confirmed if
An EPS of $0.43 or higher would confirm the bull case and likely lead to a positive market reaction.
Bear confirmed if
An EPS below $0.34 would support the bear case, indicating potential struggles in meeting market expectations.
What the market is pricing for the move.
Implied Move
±22.51%
Historical Avg
±15.2%
The options market is pricing in a significant potential move, suggesting that traders expect volatility around the earnings announcement.
Options are pricing ±22.5% while CRMD has averaged ±15.2% over the last 8 prints — setup is pricing rich.
ATM IV
0.6%
30d HV
43.4%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If CorMedix beats expectations, history suggests the stock could rise by around 2.06% on the first day after the announcement.
In line / cautious
If the results are in line with expectations, the stock may react cautiously, reflecting uncertainty in future guidance.
Miss
If the company misses expectations, history suggests a potential decline of around 11.52% in the stock price.
The lines on the call that would change the story.